To include your compound in the COVID-19 Resource Center, submit it here.

AstraZeneca, Boehringer Ingelheim, Eli Lilly, J&J, Mitsubishi Tanabe Pharma sales and marketing update

The agency said the drugs had incremental cost-effectiveness ratios (ICERs) per quality adjusted life year (QALY) of L20,000-L30,000

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE